The company has reported positive topline results from the ongoing Part 3 of the CORIST phase IIa colorectal cancer trial with the lead compound SCO-101.
A preliminary analysis of the study data shows tumor reduction supporting combination with chemotherapy, substantially increased Progression Free Survival, high Clinical Benefit Rate and consistent safety and tolerability, states the company. The results confirm previous data reported in Part 1 and 2 of the trial and support continued clinical development of SCO-101.
These results strongly support the potential of SCO-101 as a combination treatment of mCRC, a disease which is today characterized by high mortality rates and massive problems with addressing drug resistance.”
“We are very encouraged by the promising topline results reported today, not only establishing a maximum tolerated dose for this indication and drug combination, but also demonstrating impressive progression free survival for the participating patients and tumor shrinkage in a number of them. These results strongly support the potential of SCO-101 as a combination treatment of mCRC, a disease which is today characterized by high mortality rates and massive problems with addressing drug resistance. We look forward to the final analysis and to take the next step with SCO-101,” says Francois Martelet, CEO of Scandion Oncology.
Preparations for a planned CORIST next step is ongoing.
The CORIST Part 3 trial
The CORIST Part 3 trial evaluates Scandion’s lead compound SCO-101 as a combination treatment with FOLFIRI chemotherapy in 25 patients with metastatic colorectal cancer (mCRC) and previously demonstrated resistance to FOLFIRI. The 25 enrolled patients were heavily pretreated and no other active treatment options were available. Part 3 of the trial is designed to provide an optimized dose and schedule for SCO-101 and chemotherapy to ensure maximum effect in patients with mCRC.
“We are very happy with these topline results that show many encouraging signs of efficacy when combining SCO-101 and chemotherapy. These results needs to be confirmed in larger patient populations, but we are quite impressed with both the tumor reduction, median PFS and CBR observed,” says Lars Damstrup, Chief Medical Officer of Scandion Oncology.
Featured photo of Francois Martelet: Scandion Oncology